Dec. 12 at 3:22 PM
$KALV "Heads up alert! Only three days until Upcoming earnings on Monday, 12/15/2025 for
$KALV
Bullish (8.2)
KalVista Pharmaceuticals Inc.
(KALV) has recently exhibited strong performance indicators, primarily driven by the successful launch of its drug EKTERLY (sebetralstat) and promising clinical data supporting its efficacy in treating hereditary angioedema (HAE).
The company has reported robust demand for EKTERLY, which has become the first oral on-demand treatment for HAE, reflecting a significant advancement in patient care.
Financially, KalVista has shown resilience with an increase in revenue forecasts, driven by the drug's market introduction.
The company’s P/E ratio stands at a competitive level compared to its industry peers, indicating favorable valuation metrics.
Recent reports suggest a potential EPS growth trajectory as EKTERLY gains traction in the market, further enhancing investor confidence.
Analysts have noted a price target adjustment to
$28, which still signifies substantial upside potential from the current trading levels, reinforcing the bullish sentiment surrounding the stock.
Looking ahead, KalVista Pharmaceuticals is set to report its third-quarter earnings on November 11, 2025.
Historical performance has shown a consistent upward trend in revenue, largely attributed to the strategic rollout of EKTERLY.
Analyst consensus estimates suggest continued growth, with expectations of positive earnings driven by the drug's adoption and expanding market presence.
The upcoming earnings report is anticipated to provide insights into sales performance and operational efficiencies, which could further influence stock valuation and investor sentiment.
KalVista operates within the biotechnology sector, which has recently shown a positive overall performance, buoyed by advancements in drug development and regulatory approvals.
The sector's momentum is reflected in the growing interest from investors, particularly in companies that are introducing innovative treatments with clear market demand.
This backdrop positions KalVista favorably as it navigates through both market challenges and opportunities for growth.
- Funds were net buyers of
$KALV during the previous reporting quarter.
- Funds with large holdings in
$KALV include:
- Frazier Life Science, MV:
$61MM. Fund Rank: 79%
- DAFNA Capital Management LLC, MV:
$5MM. Fund Rank: 72%
www.dafnacapital.com
- Crestline Management LLC, MV:
$2MM. New position. Fund Rank: 55%
- Last 10 days performance: 25%
- Last 30 days performance: 27%
- Last 90 days performance: 21%
Some of the latest news articles:
- Title: Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
Publication Date: 12/4/2025 6:09:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/pharvaris-stock-gains-hae-drug-180900801.html?.tsrc=rss
- Title: Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment
Publication Date: 12/3/2025 9:09:55 PM, Source: yahoo
URL: https://finance.yahoo.com/m/3af9e73d-38de-30d2-a58d-017e2794432b/pharvaris-surges%2C-pulling.html?.tsrc=rss
- Title: Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects
Publication Date: 11/18/2025 11:16:51 AM, Source: yahoo
URL: https://finance.yahoo.com/news/citizens-touts-kalvista-pharmaceuticals-inc-111651248.html?.tsrc=rss
- Title: Ekterly Momentum Shows Royalty Asset Value For DRI Healthcare Trust, Says Stifel Canada
Publication Date: 11/12/2025 5:32:59 PM, Source: yahoo
URL: https://finance.yahoo.com/news/ekterly-momentum-shows-royalty-asset-173259275.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
